MediVantage Advisory
EN 中文
Book a Call
Service Offerings

Focused commercial sprints for medtech innovators

Each sprint is short, practical, and built for overseas or China-based innovators who need a clear commercial answer before committing resources. AI accelerates evidence synthesis; founder-led judgment shapes the answer.

Decision-led

Scope begins with the commercial decision, not a generic research category.

AI-enabled

Market signals, competitor context, and assumptions are synthesized quickly.

Founder-judged

Outputs are interpreted through real healthcare commercial operating experience.

Choose the decision

Go deeper into the commercialization sprint that matches your question

01 China Opportunity Snapshot 02 First Commercialization Blueprint 03 Commercialization Readiness Check

Which China opportunity should we test first?

A fast, founder-led judgment on which China use cases or segments are most realistic, where early focus should go, and what risks should shape the next decision.

Opportunity View

Where the product may realistically win, and where the China story may be overstated.

Risk Readout

Adoption barriers, reimbursement or access issues, domestic substitution, and evidence gaps.

Next Decision

Go / no-go / wait view, with 90-day priorities and assumptions to pressure-test.

What you receiveOpportunity attractiveness view, target segment prioritization, commercial risk map, and recommendation.
Best forOverseas growth-stage teams, local innovators, or investors that need a quick but credible commercial judgment before committing resources.

If we commercialize, what exactly should we do first?

A practical commercialization judgment package for teams that need to decide where to start, how to sequence early moves, and what evidence, pricing, and channel assumptions must hold.

Where To Start

Target segment, clinical scenario, hospital or customer logic, and early adoption pathway.

How To Sell

Pricing assumptions, access logic, channel options, partner criteria, and evidence priorities.

What To Do Next

A focused 6-12 month roadmap with milestones, risks, and adjustment triggers.

What you receiveFirst target logic, commercialization sequence, pricing and channel options, evidence priorities, and 6-12 month action roadmap.
Best forOverseas entrants or China-based innovators with good products but limited commercialization bandwidth.

Are we ready to explain and defend the commercialization path?

A focused readiness check that turns a product story into a clearer commercial path, gap map, and next-step action list before important investor, partner, or internal discussions.

Readiness Scorecard

Target segment, value proposition, pricing logic, evidence readiness, channel fit, and adoption barriers.

Question List

The 10-15 investor, partner, or internal questions the team should be ready to answer.

Gap Map

What is credible now, what is weak, and what must be validated in the next 30-60 days.

What you receiveCommercialization readiness scorecard, story gap map, investor / partner question list, 30-60 day action priorities, and a one-page commercial narrative.
Best forFounders, product teams, BD, strategy, or commercial leads preparing for funding, partnership, resource, or early commercialization discussions.
Next Step

Not sure which offering fits?

Start with the decision you need to make. The right sprint can be shaped around your product stage, evidence gaps, and team context.

Book a Strategy Call
Snapshot

Best when the question is which China opportunity to prioritize and what must be tested next.

Blueprint

Best when a promising product needs a first commercialization path and practical early priorities.

Readiness

Best when a team needs to check whether its commercialization logic is ready for investor, partner, or internal discussion.